In order to examine antioxidant status and lipid peroxidation in schizophrenia patients, activities of three free radical scavenging enzymes (superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT)), and the level of thiobarbituric acid-reactive substances (TBARS) as an index of lipid peroxidation have been studied in red blood cells. Schizophrenic patients were divided into three groups (disorganized (n = 21), paranoid (n = 26) and residual types (n = 18)) to determine differences between subgroups. SOD, CAT and GSH-Px activities in the control group were found to be 1461.0 ± 248.6 U g −1 Hb, 148.2 ± 59.3 k g −1 Hb and 25.87 ± 4.25 U g −1 Hb, respectively. We found no significant differences in SOD activities between study and control groups. There was a significant increase in SOD activity in the residual group compared to the paranoid group (P Ͻ 0.005). CAT activity was found to be increased in disorganized (148%), paranoid (147%), and residual (165%) groups compared to the control group. GSH-Px activity was markedly increased in the study groups except the paranoid group. Statistically significant (3-4 fold) increases in TBARS levels of red blood cells were found in all the study groups. It is proposed that antioxidant status may be changed in schizophrenia and thus may induce lipid peroxidation. Therefore, oxidative stress may have a pathophysiological role in all the subtypes of schizophrenia. Molecular Psychiatry (2001) 6, 66-73.
Introduction
Various psychologic, social, developmental, environmental, anatomic, genetic, biochemical, and other factors have been involved in the pathogenesis of schizophrenia. The hypothesis that reactive oxygen species (ROS) play an important role in schizophrenia as well as neurodegenerative disorders remains speculative and there have been no detailed studies to test this hypothesis. ROS including superoxide (O 2 ·− ), hydroxyl (·OH), hydrogen peroxide (H 2 O 2 ), singlet oxygen ( 1 O 2 ) and nitric oxide (NO·) can cause cellular injury when they are generated excessively or the enzymatic and non enzymatic antioxidant defence systems are impaired. A number of oxygenated compounds, particularly aldehydes including malondialdehyde, are produced during the attack of free radicals against membrane lipoproteins and polyunsaturated fatty acids (PUFAs). Therefore, assessment of thiobarbituric acidreactive substances (TBARS) is probably the most commonly applied method for the measurement of lipid peroxidation. 1 SOD is a potent protective enzyme that can selectively scavenge the superoxide radical (O 2 ·− ) by catalyzing its dismutation to hydrogen peroxide (H 2 O 2 ) and molecular oxygen (O 2 ). The other antioxidative enzymes, CAT and GSH-Px, act to decompose H 2 O 2 to water. 2 Assessment of the activities of these free radical scavenging enzymes in red blood cells may help to better understand the changes in antioxidative status in schizophrenia. There has also been some evidence that the antioxidant system is impaired in schizophrenia. 3, 4 Recent comparative brain proteome analyses have suggested abnormal manganese SOD (Mn-SOD) expression from the related genes and subsequently an altered antioxidant defence system in the schizophrenic hippocampus. 5 Yao et al 6 found that SOD activity but not GSH-Px and CAT activities in schizophrenia during the drug-free condition was significantly higher compared to normal control subjects. When they compared the drug-free condition with the treatment condition, SOD and GSH-Px activities, but not CAT activity were found to be lower in the treatment condition. Rachkauskas 7 found a marked increase in blood content of lipid peroxidation products, such as malondialdehyde and conjugated dienes, and CAT activity associated with a decrease in superoxide dismutase activity in different forms of schizophrenia. In a study by Yamada et al 8 there was a significant decrease in erythrocyte SOD activity in the definite tardive dyskinesia group compared to the no tardive dyskinesia and questionable groups. Mukherjee et al 9 found that SOD activity was significantly lower in the erythrocyte of schizophrenic patients compared to normal controls, with no difference in CAT and GSH-Px activities. Finally, there is a discrepancy in the study results about erythrocyte antioxidant enzymes in schizophrenia. Yet, there has been no study evaluating both erythrocyte antioxidant enzymes and lipid peroxidation in the same schizophrenic patient groups. To the best of our knowledge, there has been no study in the literature about antioxidative status and lipid peroxidation in erythrocytes from patients with different schizophrenia subgroups such as disorganized, paranoid and residual schizophrenia. The purpose of the present study was to determine: (i) red blood cell antioxidant enzymes in the different schizophrenia subgroups; (ii) lipid peroxidation levels in red blood cells; (iii) whether there is a difference and correlation between the enzyme activities and TBARS in subgroups of schizophrenic patients.
Materials and methods

Patients
The study was conducted at Adana Mental and Neurology Hospital; Gaziantep University, Faculty of Medicine, Department of Psychiatry; and Inonu University Medical Faculty, Department of Biochemistry in 1999. Informed consent was obtained from all subjects. Patients with a history of drug abuse or dependence, serious medical conditions, severe head injury or seizure disorders were excluded from the study. The diagnosis of chronic schizophrenia was established according to DSM-IV criteria on the basis of independent structured clinical interviews and review of records by two qualified psychiatrists, and included the Brief Psychiatric Rating Scale (BPRS). 10 Normal controls were healthy subjects, and none of them had a history of psychiatric disorder, severe head injury, or seizure disorder.
A total of 75 subjects were included in this study. They were divided into three groups: I-Disorganized type schizophrenic patients (n = 21) ranging in age from 19 to 58 (mean ± SD; 33.6 ± 10.8) years; II-Paranoid type schizophrenic patients (n = 36) 20-59 (34.8 ± 8.8) years; and III-Residual type schizophrenic patients (n = 18) 22-51 (34.3 ± 9.4) years. The control group consisted of 30 age and sex-matched healthy subjects ranging in age from 15 to 57 (39.7 ± 11.2) years.
All patients were treated with daily stable doses of neuroleptics (Haloperidol, Chlorpromazine, Thioridazine, Fluphenazine, Zunclopenthixole). Plasma drug levels were not available.
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Blood sampling Blood from forearm vein was collected into 5-ml Vacutainer tubes containing potassium EDTA. Some hematological parameters were tested by routine laboratory technique using an autoanalyzer (Coulter STKS, Coulter Electronics Ltd, Luton, UK). The blood samples were centrifuged at 1000 × g for 10 min at 4°C to remove plasma. The buffy coat on the erythrocyte sediment was separated carefully after the plasma was removed. The erythrocyte sediment was washed three times with 10-fold isotonic NaCl solution to remove the plasma remnant. After each procedure, erythrocytesaline mixture was centrifuged at 1000 × g for 10 min at 4°C. Aliquots of the samples were transferred into polyethylene tubes to be used in the assay of free radical scavenging enzymes and TBARS levels. Erythocyte sediment samples were stored at −80°C until analysis. After they were thawed, erythrocyte sediments were treated with 4-fold ice-cold deionized water to obtaine hemolyzate.
Enzymes, chemicals and instruments
Xanthine oxidase, xanthine, nitroblue tetrazolium (NBT), thiobarbituric acid, 1,1,3,3 tetramethoxy propane were purchased from Sigma Chemical Co (St Louis, MO, USA) and CuCl 2 , bovine serum albumin, H 2 O 2 , EDTA, Na 2 CO 3 , (NH 4 ) 2 SO 4 , chloroform, ethanol, NaCl, KH 2 PO 4 , Na 2 HPO 4 ·2H 2 O from Merck (Germany). LKB Biochrom Ultraspec Plus uv/visible spectrophotometer (Cambridge, UK) was used to measure SOD, CAT and GSH-Px activities, and Fluorescence Spectrophotometer (Hitachi model F-4010, Japan) was used to measure TBARS levels.
CAT activity determination Catalase (EC 1.11.1.6) activity was determined by the method of Aebi.
11 The principle of the assay is based on the determination of the rate constant k (dimension: s
) of the hydrogen peroxide decomposition. By measuring the absorbance changes per minute, the rate constant of the enzyme was determined. Activities were expressed as k g −1 Hb.
SOD activity determination Total (Cu-Zn and Mn) SOD (EC 1.15.1.1) activity was determined according to the method of Sun et al 12 and a slightly modified method by Durak et al. 13 The principle of the method is based on the inhibition of NBT reduction by the xanthine-xanthine oxidase system as a superoxide generator. Activity was assessed in the ethanol phase of the lyzate after 1.0 ml ethanol/chloroform mixture (5/3, v/v) was added to the same volume of the hemolyzate and centrifuged.
14 One unit of SOD was defined as the enzyme amount causing 50% inhibition in the NBT reduction rate. SOD activity was also expressed as Units per gram hemoglobin.
GSH-Px activity determination GSH-Px (EC 1.6.4.2) activity was measured by the method of Paglia et al. 15 The enzymatic reaction was initiated by addition of H 2 O 2 to the reaction mixture containing reduced glutathione, NADPH and glutathione reductase and the change in the absorbance at 340 nm was monitored by spectrophotometer. Activity was given in international units per gram hemoglobin.
TBARS levels determination TBARS was estimated according to the method of Wasowicz et al
16 with minor changes. The principle of the method is based on the coupling of TBARS with thiobarbituric acid (TBA) at 95°C. All measurements (standards and samples) were done at the upper n-butanol phase of the reaction mixture. Results were expressed as micromoles per gram hemoglobin.
Statistical analysis
Data were analyzed by using SPSS® for Windows computing program. Non parametric statistical methods were used to analyze the data. Mann-Whitney U tests were used for pairwise comparisons. Bivariate comparisons were examined using Pearson rank correlation coefficients (r) and values were corrected for ties. Twotailed significance values were used. A P value less than 0.05 was accepted as significant.
Results
As to the social and demographic data (age, sex, etc), patients and their controls showed homogeneity and there were no significant differences between the groups (P Ͼ 0.05). Results are summarized in Tables  1-6. Table 1 shows significant increases in CAT and GSH-Px activities and in TBARS levels in all the study groups compared to the control group. However, there was no significant difference in TBARS levels between the study groups.
The mean levels of hematologic parameters in schizophrenia patients and their controls are presented in Table 2 . There was a significant decrease in MCH value in residual type schizophrenia and in MCHC value in all the study groups compared to the control group (P Ͻ 0.002 in disorganized and residual groups, and P Ͻ 0.0001 in paranoid group). WBC counts were found to be significantly elevated in disorganized and residual subgroups compared to the control group (P Ͻ 0.02 and P Ͻ 0.02, respectively). There were no significant differences among the age groups of schizophrenic patients in any parameter tested in this study (Table 3) . When all the schizophrenic patients were divided into two groups, those with (n = 9) and without (n = 66) tardive dyskinesia, no significant differences were observed between the two groups in antioxidant enzymes activities and TBARS levels ( Table 4) . We did not find any significant difference in the test parameters between male and female subjects in both schizophrenia and control groups. However, there were significant differences among the study and control subjects with the same gender in some test parameters (Table 5 ).
In the correlation analysis, there were generally significant positive correlations between the activities of antioxidant enzymes in erythrocytes from the study and control groups (Table 6 ).
Discussion
We have preferred red blood cells as a cell pattern to estimate the activities of the free radical scavenging enzymes in schizophrenic patients because these enzymes are constitutively expressed in most cells including immature erythrocytes, and erythrocytes are easy to obtain. The elevated activities of RBC antioxidant enzymes in the subtypes of schizophrenia might be a peripheral response of the organism to increased free oxygen radicals (such as O 2 ·− , ·OH, 1 O 2 and H 2 O 2 ) There is no statistically significant difference between the two groups. production in the central nervous system. Many research groups have reported elevated RBC SOD activity in schizophrenia patients compared to normal controls [17] [18] [19] whereas some others have found normal SOD activity. 20 Our results have confirmed those of Siner et al 20 that SOD, CAT and GSH-Px have complementary activities in the antioxidative defence system. For example, H 2 O 2 , the product of a reaction catalysed by SOD, is also the substrate for CAT and GSHPx (Figure 1 ). We have found increased CAT and GSHPx activities, but not SOD activity in erythrocytes of patients from all schizophrenia subgroups compared to their controls. Abdalla et al 19 found that both neuroleptic-treated and untreated schizophrenic patients exhibited lower activities of erythrocytic GSH-Px than did normal individuals. This finding is in contrast to our result as well as to previous reports. 10, 17, 21 Increased Figure 1 Schematic representation of cellular enymatic antioxidant systems and the lipid peroxidation process. O 2 · − superoxide; SOD, superoxide dismutase; CAT, catalase; H 2 O 2 hydrogen peroxide; GSH-Px, glutathione peroxidase; GSH, reduced glutathione; GSSG, oxidized glutathione; GSH-Red, glutathione reductase; ·OH, hydroxyl radical (the most potent free oxygen radical); PUFA, polyunsaturated fatty acid; TBARS, thiobarbituric acid-reactive substances.
antioxidant enzyme activities may reflect a preceding cellular oxidative stress or serve as a compensatory mechanism. On the other hand, the fact that SOD activity did not change in patient groups despite cellular oxidative stress may possibly lead to an increase in the activities of other antioxidant enzymes, CAT and GSH-Px. Another possibility is over-production of H 2 O 2 in plasma or erythrocytes. Since H 2 O 2 is a neutral and highly liposoluble compound that can easily pass through the cytoplasmic and subcellular membranes, an excess amount of H 2 O 2 found in or out of the cell membrane can pass through the erythrocyte membrane into the cytosol and thus cause an increase in the activities of CAT and GSH-Px. Mature RBCs do not have nucleus and these enzyme proteins could not be expressed in such anucleated cells, but the activities (not amounts) of these enzymes can be regulated by several mechanisms such as covalent modifications. The activation of an enzyme may result from substrate overload in cellular matrix, for example, the overload of H 2 O 2 for CAT and GSH-Px enzymes.
The fact that erythrocyte TBARS levels in patient groups were increased 3-4 fold compared to controls suggests increased lipid peroxidation and thus oxidative stress still existed despite increased activities of the antioxidant enzymes. Several experimental and clinical studies in the literature 22, 23 reported that neuroleptics could suppress superoxide production in brain homogenates. Similarly, SOD activity did not change in patients with schizophrenia, because they all used neuroleptic drugs for their treatment. However, Yao et al 6 suggested that haloperidol, a neuroleptic drug, had no regulatory action on the antioxidative defence system. At baseline, they found no significant differences for all three enzymes between patients and controls, and in the drug-free period, they found increased SOD activity, but not CAT and GSH-Px activities. SOD and GSH-Px activities, but not CAT activity were higher in the drug-free condition than the treatment condition. 6 In the other previous reports, antioxidant enzyme activities were not found to be related to plasma haloperidol levels. 17, 19, 24 The major limitation in our study is that the patient group differed from the control group, in two respects; their illness and their drug treatment. It is difficult to be certain whether it is the illness or the drugs which caused the difference in the parameters studied. In a study with on-off haloperidol treatment design compared with age-and gendermatched normal control subjects, there were no significant treatment effects on human plasma GSH-Px levels (but not activities), but the levels of enzyme GSH-Px were significantly and positively correlated with psychosis rating scores in patients both on and off haloperidol treatment. 25 However, studies in untreated schizophrenic patients also have some problems, in that differences between schizophrenic subgroups and controls might be related to the non-specific severe stress of an acute illness rather than to an ongoing process specific to schizophrenia. Taken together, the changes in the activities of the antioxidant enzymes in schizophrenic patients seem to be independent from antipsychotic treatment and may reflect the pathological process of the disease. On the other hand, drugs may partially attenuate abnormalities seen in unmedicated schizophrenic patients.
A potential sequela to the long-term treatment of schizophrenia with neuroleptics is tardive dyskinesia. The underlying pathology is not known, although lipid peroxidation and neuroleptic-induced neuronal damage by ROS (from the metabolism of endogenous catecholamines or of the drugs used) have been postulated as a possible mechanism. 26 Tsai et al 27 found a positive correlation between symptoms of tardive dyskinesia and the levels of N-acetylaspartate, N-acetylaspartylglutamate and aspartate, markers for excitatory neurotransmission, in CSF and also markers for oxidative stress such as carbonyl groups of proteins in CSF, but a negative correlation between tardive dyskinesia Molecular Psychiatry symptoms and CSF SOD activity. However, in our study no difference was found between patients with and without symptoms of tardive dyskinesia in both antioxidative enzyme activities and TBARS levels. Contrary to our results, it has been suggested in both human and animal studies that oxidative injury may play a role in the pathogenesis of neuroleptic-induced movement disorder (ie tardive dyskinesia) and that supplement of Vitamin E (dosages Ն400 IU day −1 ) and other antioxidant agents such as selegiline 28 to neuroleptics could be efficacious in its treatment. [29] [30] [31] According to our study results, a possible role for oxidative stress in the pathogenesis of tardive dyskinesia does not seem to be considerable. However, increased antioxidative enzyme activities and TBARS levels in patients with schizophrenia compared to controls may notify the existence of a possible oxidative stress.
Reduced levels of phospholipids and PUFAs in erythrocyte membranes 32 39 have recently found that the amounts of phosphatidylcholine and phosphatidylethanolamine reduced in postmortem brain tissue from schizophrenic patients compared to those from the control group. Abnormalities in membrane fatty acid metabolism and therapeutic trials of fatty acid in schizophrenia were discussed in a review article. 40 In this article, investigators have suggested that abnormalities in fatty acid metabolism are not specific to schizophrenia and have also been reported in other conditions including depression, 41 alcoholism, 42 movement disorders, 43 and generalized peroxisomal disorders. 44 Increased TBARS levels in erythrocyte from our schizophrenia patients are consistent with the previous results. 32, 33 Membrane PUFAs are more prone to lipid peroxidation by ROS than the other lipids such as cholosterol and saturated fatty acids. Obviously, PUFA and phospholipids in biological membranes are destroyed and thus reduced in amount through the lipid peroxidation process. Essential fatty acid depletion in the membrane and, consequently, cell injury might result from excessive free radical generation or an impaired antioxidant defence system. 3 Excessive free radical generation is very important particularly in the cell membrane. One of the major ROS producing pathways in the membranes is prostaglandin synthesis (Figure 1) . Phospholipase A2 plays an important role in the metabolism of phospholipids by initiating the release of arachidonic acid from membrane triacylglyceroles. Platelet 45 and plasma 46 activities of phospholipase A2, the first enzyme in the prostaglandin synthesis, were found to be elevated in drug-free schizophrenic patients compared to healthy and psychiatric controls and decreased after neuroleptic treatment. The subsequent metabolism of arachidonic acid by two different enzyme systems, cyclooxygenase and lipoxygenase, involves the formation of free radicals that can lead to continuous lipid peroxidation. In addition, prostaglandin E2 in CSF 47 and plasma, 48 and prostaglandin E1 in CSF 47 were found to be increased, although not conclusively. 49, 50 The increase in the ROS in the RBC membrane through the mechanism mentioned above might be the reason for the decreased phospholipid amount and increased TBARS levels. The other possible explanation for the increased TBARS levels in red blood cells from patients in schizophrenia subgroups is increased catecholamine metabolism and a resultant overproduction of ROS following neuroleptic drug treatment. 51 In conclusion, oxidative stress may have a pathophysiological role in all the subtypes of schizophrenia. The possible explanation is that the central nervous system may be more vunerable to ROS-mediated injury than other tissues mainly for three reasons: a high rate of oxidative metabolic activity; a high concentration of readily oxidisable substrate, in particular, membrane lipid PUFAs; and a high ratio of membrane surface area to cytoplasmic volume. 52 Supplementation of nonenzymatic antioxidant compounds, including vitamin E, C, and ␤-carotenes in addition to the treatment of schizophrenia, 51 ,53 may protect membranous structures from lipid peroxidation. Beside antioxidant properties, vitamin C and E have been shown to interact with the brain's catecholamines. 54 By these two different ways, it might be possible to produce a remarkable improvement in some symptoms of schizophrenia. Further investigations with a larger cohort of schizophrenic patients are needed to provide definitive data about the antioxidant therapy.
